The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib

재발성 비소세포성 폐암환자의 Afatinib과 삼칠충초정 병용투여 경과관찰 1례

  • Kim, Jee-hye (East West Cancer Center, Dunsan Korean Medicine Hospital of Dae-Jeon University) ;
  • Bae, Kyeo-re (East West Cancer Center, Dunsan Korean Medicine Hospital of Dae-Jeon University) ;
  • Park, So-jung (East West Cancer Center, Dunsan Korean Medicine Hospital of Dae-Jeon University) ;
  • Cho, Chong-kwan (East West Cancer Center, Dunsan Korean Medicine Hospital of Dae-Jeon University) ;
  • Yoo, Hwa-seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Dae-Jeon University)
  • 김지혜 (대전대학교 둔산한방병원 동서암센터) ;
  • 배겨레 (대전대학교 둔산한방병원 동서암센터) ;
  • 박소정 (대전대학교 둔산한방병원 동서암센터) ;
  • 조종관 (대전대학교 둔산한방병원 동서암센터) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터)
  • Received : 2017.02.22
  • Accepted : 2017.03.30
  • Published : 2017.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study is to report the case of a patient with recurring non-small cell lung carcinoma (NSCLC) taking Samchilchoongcho-Jung with Afatinib. Methods: An NSCLC patient diagnosed with multiple bone and pulmonary metastasis was taking Afatinib (20 mg/day) and suffering from stomatitis caused by the Afatinib. The patient was treated with Samchilchoongcho-Jung (1,500 mg/ day) for 3 months. The tumor size was measured with computed tomography, and laboratory findings, including tumor markers (CEA, Cyfra 21-1), were also followed up. Stomatitis was measured by a numeric rating scale, and adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0. Results: After combined treatment, stable disease was shown on computed tomography. The tumor marker levels of CEA and Cyfra 21-1 were decreased, and the stomatitis significantly improved. NCI-CTCAE 4.0 showed no adverse events. Conclusion: This case study suggests that Samchilchoongcho-Jung may have a synergic effect, in conjunction with Afatinib, on the treatment of patients with recurring NSCLC.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30. https://doi.org/10.3322/caac.21387
  2. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL Rowland JH, et al. Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 2016;66(4):271-89. https://doi.org/10.3322/caac.21349
  3. Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers(Basel) 2015;7(3):1815-46. https://doi.org/10.3390/cancers7030864
  4. Xu M, Xie Y, Ni S, Liu H. The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer. Ann Transl Med 2015;3(7):96. https://doi.org/10.3978/j.issn.2305-5839.2015.03.60
  5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancerharbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8. https://doi.org/10.1016/S1470-2045(09)70364-X
  6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239-46. https://doi.org/10.1016/S1470-2045(11)70393-X
  7. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutationpositive lung adenocarcinoma(LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16(2):141-51. https://doi.org/10.1016/S1470-2045(14)71173-8
  8. Park SC, Yoo HS, Cho CK, Lee YW. Recent Experimental Tendency for Herbal Medicines Treating Lung Cancer in South Korea. J of Kor Traditional Oncology 2008;13(1):43-54.
  9. Zheng HM, Yoon JW, Lee YW, Cho CK, Oh DS, Yoo HS. Case Series of Advanced Non-small Cell Lung Cancer Patients Treated with Han-Am-Plus. Korean J Orient Int Med 2011;32(1):113-20.
  10. Kwon EM, Jerng UM, Kim KS, Lee SK, Choi WC, Yoon SW. Two Cases of Non-small Cell Lung Cancer Patients Treated with Allergen Removed Rhus Verniciflua Stokes Based Traditional Korean Medicine and Chemotherapy. J of Kor Traditional Oncology 2009;14(1):13-20.
  11. Li SG, Chen HY, Ou-Yang CS, Wang XX, Yang ZJ, Tong Y, et al. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013;8(2):e57604. https://doi.org/10.1371/journal.pone.0057604
  12. Kang HJ, Park SJ, Park YM, Yoo HS, Kang IC. Inhibitory effects of HangAmDan-B1 (HAD-B1) on A549 lung cancer cell proliferation and tumor growth in a xenograft model. Academia Journal of Scientific Research 2016;4(7):187-93.
  13. Chang SH. Letter to Editor : Gamchosasim-tang, Sawi-tang and Giotrif Combination Therapy for Metastatic Non-Small-Cell Lung Adenocarcinoma ; A Regression Case. J of Kor Traditional Oncology 2015;20(2):1-4. https://doi.org/10.15432/JKTO.2015.20.2.001
  14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1). Eur J Cancer 2009;45(2): 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  15. National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.4.0, 2010. Available at http://evs.nci.nih.gov/ftp1/CTCAE/About.html
  16. Ministry of health & wellfare, Korea central cancer registry, National cancer center. Annual report of cancer statistics in Korea in 2014. 2016.
  17. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinicallung cancer models. Oncogene 2008;27(34):4702-11. https://doi.org/10.1038/onc.2008.109
  18. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung(LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015;16(8):897-907. https://doi.org/10.1016/S1470-2045(15)00006-6
  19. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17(5):577-89. https://doi.org/10.1016/S1470-2045(16)30033-X
  20. Lee CY, Hsieh SL, Hsieh S, Tsai CC, Hsieh LC, Kuo YH, et al. Inhibition of human colorectal cancer metastasis by notoginsenoside R1, an important compound from Panax notoginseng. Oncol Rep 2017;37(1):399-407. https://doi.org/10.3892/or.2016.5222
  21. Chou PY, Huang GJ, Pan CH, Chien YC, Chen YY, Wu CH, et al. Trilinolein inhibits proliferation of human non-small cell lung carcinoma A549 through the modulation of PI3K/Akt pathway. Am J Chin Med 2011; 39(4):803-15. https://doi.org/10.1142/S0192415X11009214
  22. Bizarro A, Ferreira IC, Sokovic M, van Griensven LJ, Sousa D, Vasconcelos MH, et al. Cordyceps militaris(L.) Link Fruiting Body Reduces the Growth of a Non-Small Cell Lung Cancer Cell Line by Increasing Cellular Levels of p53 and p21. Molecules 2015;20(8):13927-40. https://doi.org/10.3390/molecules200813927
  23. Yu X, Ling J, Liu X, Guo S, Lin Y, Liu X, et al. Cordycepin induces autophagy-mediated c-FLIPL degradation and leads to apoptosis in human non-small cell lung cancer cells. Oncotarget 2017;8(4):6691-9.
  24. Wang L, Li X, Song YM, Wang B, Zhang FR, Yang R, et al. Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to $\gamma$ -radiation by targeting the nuclear factor-${\kappa}B$ pathway. Mol Med Rep 2015;12(1):609-14. https://doi.org/10.3892/mmr.2015.3397
  25. Khan MA, Ali R, Parveen R, Najmi AK, Ahmad S. Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from Boswellia serrata. J Ethnopharmacol 2016;191: 315-23. https://doi.org/10.1016/j.jep.2016.06.053
  26. Choi YJ, Shin DY, Lee YW, Cho CK, Kim GY, Kim WJ, et al. Inhibition of cell motility and invasion by HangAmDan-B in NCI-H460 human non-small cell lung cancer cells. Oncology Reports 2011;26(6):1601-9. https://doi.org/10.3892/or.2011.1440

Cited by

  1. 고밀도 인공물 환자에서 반복적 재구성 사용 유무에 따른 3차원 입체조형 방사선 치료 계획 인자의 정량분석 vol.14, pp.1, 2017, https://doi.org/10.7742/jksr.2020.14.1.7
  2. Afatinib 표적항암치료를 시행 중인 흉막 전이된 비소세포폐암 환자의 한방치료 증례보고 vol.41, pp.6, 2017, https://doi.org/10.22246/jikm.2020.41.6.1255